Comparing Clinical Characteristics and Outcomes of <i>MYC</i> and <i>BCL6</i> Double Hit Lymphoma (DHL- <i>BCL6</i>) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications
Arushi Khurana(Mayo Clinic in Arizona), Rebecca L. King(Mayo Clinic in Arizona), Giorgio Inghirami(Cornell University), Richard Burack(University of Rochester Medical Center), Jonathon B. Cohen(Emory University), Thomas M. Habermann(Mayo Clinic in Arizona), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Izidore S. Lossos(University of Miami), Matthew J. Maurer(Mayo Clinic in Arizona), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Brad S. Kahl(UW Health University Hospital), James R. Cerhan(Mayo Clinic), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Brian K. Link(University of Iowa), Timothy J. McDonnell(Health Service Executive), Raphael Mwangi(Mayo Clinic in Arizona), Andrew L. Feldman(Mayo Clinic in Arizona), Sergei Syrbu(University of Iowa), Jennifer R. Chapman‐Fredricks(University of Miami), Kiran Vij(Washington University in St. Louis)
Cited by 8
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k